[{"address1": "3000 Pegasus Park Drive", "address2": "Suite 1430", "city": "Dallas", "state": "TX", "zip": "75247", "country": "United States", "phone": "214 612 0000", "website": "https://www.tayshagtx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 52, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sean P. Nolan", "age": 55, "title": "CEO & Chairman", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 925331, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sukumar  Nagendran M.D.", "age": 56, "title": "President, Head of Research & Development and Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 820594, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamran  Alam CPA, M.B.A.", "age": 45, "title": "CFO & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 573362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hayleigh  Collins", "title": "Director of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy M. Porter SPHR", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederick  Porter Ph.D.", "title": "Chief of Staff & Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  McGinnis M.P.H.", "title": "Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  McAuliffe", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven  Gray Ph.D.", "title": "Chief Scientific Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Berge  Minassian M.D.", "title": "Chief Medical Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.42, "open": 1.42, "dayLow": 1.4, "dayHigh": 1.52, "regularMarketPreviousClose": 1.42, "regularMarketOpen": 1.42, "regularMarketDayLow": 1.4, "regularMarketDayHigh": 1.52, "beta": 0.414, "forwardPE": -3.5714288, "volume": 4159017, "regularMarketVolume": 4159017, "averageVolume": 2132748, "averageVolume10days": 5310970, "averageDailyVolume10Day": 5310970, "bid": 1.47, "ask": 1.52, "bidSize": 1700, "askSize": 1700, "marketCap": 307414528, "fiftyTwoWeekLow": 1.19, "fiftyTwoWeekHigh": 4.32, "priceToSalesTrailing12Months": 23.880566, "fiftyDayAverage": 1.9788, "twoHundredDayAverage": 2.385525, "currency": "USD", "enterpriseValue": 192974960, "floatShares": 122283522, "sharesOutstanding": 204943008, "sharesShort": 20704276, "sharesShortPriorMonth": 19827995, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.101, "heldPercentInsiders": 0.17538, "heldPercentInstitutions": 0.78211, "shortRatio": 10.85, "shortPercentOfFloat": 0.1333, "bookValue": 0.541, "priceToBook": 2.7726433, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -114335000, "trailingEps": -0.49, "forwardEps": -0.42, "enterpriseToRevenue": 14.991, "enterpriseToEbitda": -2.549, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TSHA", "underlyingSymbol": "TSHA", "shortName": "Taysha Gene Therapies, Inc.", "longName": "Taysha Gene Therapies, Inc.", "firstTradeDateEpochUtc": 1600954200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "fa02d192-bc05-33bd-8c2b-2973d0bcc5d6", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.5, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.41, "targetMedianPrice": 7.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 172743008, "totalCashPerShare": 0.843, "ebitda": -75716000, "totalDebt": 58303000, "quickRatio": 5.055, "currentRatio": 5.222, "totalRevenue": 12873000, "debtToEquity": 53.554, "revenuePerShare": 0.064, "returnOnAssets": -0.34166, "returnOnEquity": -3.18686, "freeCashflow": -53947500, "operatingCashflow": -75368000, "revenueGrowth": -0.536, "grossMargins": 1.0, "operatingMargins": -19.15378, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-11"}]